参考文献/References:
[1].Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
[2].Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort[J]. BMJ,2009,339:b4606.
[3].Patnaik JL, Byers T, DiGuiseppi C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study[J]. Breast Cancer Res,2011,13(3):R64.
[4].Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy[J]. J Am Coll Cardiol,2010, 55(3):213-220.
[5].Guo Q, Wu LM, Wang Z, et al. Early detection of silent myocardial impairment in drug-naive patients with new-onset systemic lupus erythematosus[J]. Arthritis Rheumatol,2018,70(12):2014-2024.
[6].Ntusi NA,Piechnik SK,Francis JM,et al. Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis—a clinical study using myocardial T1-mapping and extracellular volume quantification[J]. J Cardiovasc Magn Reson,2014,16:21.
[7].Hall PS, Harshman LC, Srinivas S, et al. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients[J]. JACC Heart Fail,2013,1(1):72-78.
[8].Plana JC,Galderisi M,Barac A,et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy:a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. Eur Heart J Cardiovasc Imaging,2014,15(10):1063-1093.
[9].Alexander J,Dainiak N,Berger HJ,et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography[J]. N Engl J Med, 1979,300 (6):278-283.
[10].Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy:comparison of echocardiography and cardiac magnetic resonance imaging[J]. J Clin Oncol,2012,30(23):2876-2884.
[11].Drafts BC,Twomley KM,D’Agostino R Jr,et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease[J]. JACC Cardiovasc Imaging,2013,6(8):877-885.
[12].Harries I, Biglino G, Baritussio A, et al. Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy[J]. Int J Cardiol,2019,pii: S0167-5273(19)30293-1(article in press).
[13].Jordan JH,Sukpraphrute B,Melendez GC,et al. Early myocardial strain changes during potentially cardiotoxic chemotherapy may occur as a result of reductions in left ventricular end-diastolic volume: the need to interpret left ventricular strain with volumes[J]. Circulation,2017,135(25):2575-2577.
[14].Jordan JH,Castellino SM,Melendez GC,et al. Left ventricular mass change after anthracycline chemotherapy[J]. Circ Heart Fail,2018,11(7):e004560.
[15].Neilan TG,Coelho-Filho OR,Pena-Herrera D,et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines[J]. Am J Cardiol,2012,110(11):1679-1686.
[16].Ferreira de Souza T,Quinaglia ACST,Osorio Costa F,et al. Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease[J]. JACC Cardiovasc Imaging,2018,11(8):1045-1055.
[17].Ewer MS,Ali MK,Mackay B,et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin[J]. J Clin Oncol, 1984,2 (2):112-117.
[18].Thavendiranathan P,Poulin F,Lim KD,et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy:a systematic review[J]. J Am Coll Cardiol,2014,63(25 Pt A):2751-2768.
[19].Ong G,Brezden-Masley C,Dhir V,et al. Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy[J]. Int J Cardiol,2018,261:228-233.
[20].Romano S,Judd RM,Kim RJ,et al. Association of feature-tracking cardiac magnetic resonance imaging left ventricular global longitudinal strain with all-cause mortality in patients with reduced left ventricular ejection fraction[J]. Circulation,2017,135(23):2313-2315.
[21].Negishi T,Thavendiranathan P,Negishi K,et al. Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: The SUCCOUR Trial[J]. JACC Cardiovasc Imaging,2018,11(8):1098-1105.
[22].Jolly MP,Jordan JH,Melendez GC,et al. Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy[J]. J Cardiovasc Magn Reson,2017,19(1):59.
[23].Fallah-Rad N,Lytwyn M,Fang T,et al. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy[J]. J Cardiovasc Magn Reson,2008,10:5.
[24].Fallah-Rad N,Walker JR,Wassef A,et al. The utility of cardiac biomarkers,tissue velocity and strain imaging,and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor Ⅱ-positive breast cancer treated with adjuvant trastuzumab therapy[J]. J Am Coll Cardiol,2011,57(22):2263-2270.
[25].Bernaba BN,Chan JB,Lai CK,et al. Pathology of late-onset anthracycline cardiomyopathy[J]. Cardiovasc Pathol,2010,19(5):308-311.
[26].Galán-Arriola C,Lobo M,Vilchez-Tschischke JP,et al. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity[J]. J Am Coll Cardiol,2019,73(7):779-791.
[27].Neilan TG,Coelho-Filho OR,Shah RV,et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy[J]. Am J Cardiol,2013,111(5):717-722.
[28].Wassmuth R,Lentzsch S,Erdbruegger U,et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study[J]. Am Heart J,2001,141(6):1007-1013.
[29].Keramida K,Farmakis D,Bingcang J,et al. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients[J]. Eur J Heart Fail,2019,21(4):529-535.
[30].Barthur A,Brezden-Masley C,Connelly KA,et al. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab:a prospective observational study[J]. J Cardiovasc Magn Reson,2017,19(1):44.
[31].Ylanen K, Poutanen T, Savikurki-Heikkila P, et al. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer[J]. J Am Coll Cardiol,2013,61(14):1539-1547.
[32].Yu AF,Chan AT,Steingart RM. Cardiac magnetic resonance and cardio-oncology: does T2 signal the end of anthracycline cardiotoxicity?[J]. J Am Coll Cardiol,2019,73(7):792-794.
相似文献/References:
[1]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[2]吴洋.左室心肌致密化不全的心脏磁共振诊断[J].心血管病学进展,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
WU Yang.Diagnosis of Left Ventricular Non-compaction Cardiomyopathy With Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
[3]徐源蔚 陈玉成.心脏磁共振在检测自身免疫性风湿疾病心脏受累中的应用进展[J].心血管病学进展,2019,(5):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]
XU Yuanwei,CHEN Yucheng.Advances in the Application of Cardiac Magnetic Resonance in Detecting Cardiac Involvement in Autoimmune Rheumatic Disease[J].Advances in Cardiovascular Diseases,2019,(5):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]
[4]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[5]金荣杰 徐勇 邓珏琳 沈明志.应用心脏磁共振评估前列地尔对ST段抬高型心肌梗死患者心肌灌注的影响[J].心血管病学进展,2020,(10):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
JIN RongjieXU YongDENG JuelinSHEN Mingzhi.Effect of Alprostadil on Myocardial Perfusion of Patients with ST Segment Elevation Myocardial Infarction Directly Receiving Percutaneous Coronary Intervention Assessed with Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(5):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
[6]张宁 王嫱.心脏磁共振评估特发性炎症性肌病患者心脏受累的研究进展[J].心血管病学进展,2020,(11):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
ZHANG Ning,WANG Qiang.Advances in Evaluating Cardiac Involvement in Idiopathic Inflammatory Myopathy by Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(5):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
[7]陈小玲 陈玉成.肺高压心肌纤维化磁共振评价及临床意义[J].心血管病学进展,2021,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.010]
CHEN Xiaoling,CHEN Yucheng.Cardiac Magnetic Resonance Evaluation and the Clinical Value of Myocardial Fibrosis in Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2021,(5):135.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.010]
[8]尹丽丹 蒲守芳 何娟 陈玉成.右心室评价方法及其临床应用[J].心血管病学进展,2021,(6):521.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.011]
YIN Lidan,PU Shoufang,HE Juan,et al.The Methods to Evaluation of Right Ventricular and its Clinical Application[J].Advances in Cardiovascular Diseases,2021,(5):521.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.011]
[9]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(5):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[10]蒲华霞 彭礼清.系统性红斑狼疮心脏受累的MRI评价进展[J].心血管病学进展,2021,(8):716.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.011]
PU huaxia,PENG Liqing.Magnetic Resonance Imaging in the Evaluation of Cardiac Involvement in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2021,(5):716.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.011]